Bedaquiline in the treatment of patients with co-infection HIV/tuberculosis

A. Galstyan (Moscow, Russian Federation), S. Borisov (Moscow, Russian Federation), M. Sinitsin (Moscow, Russian Federation)

Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Session: Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Session type: Thematic Poster
Number: 4741
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Galstyan (Moscow, Russian Federation), S. Borisov (Moscow, Russian Federation), M. Sinitsin (Moscow, Russian Federation). Bedaquiline in the treatment of patients with co-infection HIV/tuberculosis. 4741

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Bedaquiline in treatment of TB/HIV co-infection patients with extremely-drug resistance of MBT
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018

Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019


Immunologic recovery in HIV/TB co-infected patients after anti-TB treatment
Source: Annual Congress 2009 - Tuberculosis and HIV co-infection
Year: 2009


Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019
Year: 2020



Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly
Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018
Year: 2019



The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis
Source: International Congress 2019 – Tuberculosis: treatment and management
Year: 2019


Non-tuberculous infections in patients with anti-TNF treatment
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010


Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection
Source: ISSN=ISSN 1810-6838, ISBN=, page=190
Year: 2006

The (in)significance of TB and COVID-19 co-infection
Source: Eur Respir J, 56 (2) 2002105; 10.1183/13993003.02105-2020
Year: 2020



Treatment outcomes of MDR-TB and HIV co-infection in Europe
Source: Eur Respir J, 49 (6) 1602363; 10.1183/13993003.02363-2016
Year: 2017



Adverse effects among MDR/XDR TB patients with viral hepatitus appearing during TB chemotherapy
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020


Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline
Source: International Congress 2019 – Tuberculosis: a public health approach
Year: 2019

Experience of Bedaquiline use in treatment of XDR-TB patients
Source: International Congress 2017 – TB: diagnosis, severity and practical management
Year: 2017

Non-tuberculous infections in patients with TNF-alpha-antagonist treatment
Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections
Year: 2011

Retreatment of tuberculosis patients after the treatment interruption
Source: Eur Respir J 2006; 28: Suppl. 50, 506s
Year: 2006

Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010


Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment
Source: Annual Congress 2007 - Clinical tuberculosis
Year: 2007


Timing of relapse of tuberculosis in people with co-infection (HIV/TB)
Source: Virtual Congress 2020 – Tuberculosis and comorbidities
Year: 2020


Efficiency of treatment regimens for chronic tuberculosis patients
Source: Eur Respir J 2003; 22: Suppl. 45, 519s
Year: 2003

The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010